At the 2024 AAD conference, Longbio Pharma showcased encouraging early-stage findings for their drug LP-003.

10xBio Reveals Interim Phase 2b Trial Outcomes Indicate Enhanced Effectiveness of New Treatment in Submental Fat Reduction.

Initial stage of the onCARlytics study focusing on solid cancers moves forward to explore combined therapeutic approaches.

Johnson & Johnson has filed a supplementary application with the FDA for the authorization of TREMFYA® (guselkumab) aimed at treating moderate to severe ulcerative colitis in adults.

Domain Therapeutics and Chime Biologics have entered into a production deal to push forward a new CCR8-targeting antibody for use in treating cancer through immunotherapy.

Monte Rosa Therapeutics has commenced preclinical trials for its novel compound MRT-8102, a pioneering NEK7-targeted molecular glue degrader with additional capabilities of impeding the NLRP3/IL-1β signaling cascade.

Aprea Therapeutics reveals it has received FDA authorization for its investigational new drug, APR-1051, a novel WEE1 kinase blocker targeting cancers with high Cyclin E levels.

AbilityPharma Secures Funding of €7M for Progressing Phase 2b Trials of ABTL0812, an Autophagy-Stimulating Drug, in Treating Spread-Out Pancreatic Cancer.

Ranok Therapeutics broadens its clinical trials for its BRD4 protein degradation agent RNK05047, now including tests in China.

ASLAN Pharmaceuticals Offers Update on TREK-DX Research and Emphasizes Eblasakimab's Effectiveness for Patients with Atopic Dermatitis Previously Treated with Dupilumab.

MoonLake reveals notable advancements using Nanobody® sonelokimab over a six-month period for treating active psoriatic arthritis (PsA), along with other crucial updates during its research and development event.

Latest findings from the second phase of testing indicate that amlitelimab may be a top-performing contender for sustained treatment effectiveness in managing eczema.